ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer and graft-versus-host-disease (GvHD), a type of auto-immune disease. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor-modified T cells (CAR-T), T-cell receptor (TCR)-modified T cells, and other adoptive cell-based approaches that use non-viral and viral gene transfer methods for broad scalability. The approach is based on generating products from patients (autologous) as well as from third party (allogeneic) as off-the-shelf therapy. The Company is utilizing Intrexon's proprietary gene control approaches such as its RheoSwitch® platform and advancing programs in multiple stages of development. The Company's preclinical and clinical pipeline focuses on the treatment of hematological and solid tumor malignancies, as well as GvHD, using cellular therapeutics.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.